Short

Global Mobile Value Added Services (MVAS) Strategic Analysis Report 2023-2030 - Robust Outlook for Location-Based Advertising Spurs Demand for Location-based MVAS

Retrieved on: 
Thursday, September 21, 2023

DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Mobile Value Added Services (MVAS): Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Mobile Value Added Services (MVAS): Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Mobile Value Added Services (MVAS) estimated at US$723.4 Billion in the year 2022, is projected to reach a revised size of US$2 Trillion by 2030, growing at a CAGR of 13.2% over the analysis period 2022-2030.
  • This robust growth is fueled by technological advancements, market diversifications and increased demand for wireless application protocols.
  • The Mobile Value Added Services (MVAS) market in the U.S. is estimated at US$148.9 Billion in the year 2022.

Rocket and Missile Market worth $77.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 14, 2023

Based on speed, the Rocket and missile market has been segmented into subsonic, supersonic, and hypersonic.

Key Points: 
  • Based on speed, the Rocket and missile market has been segmented into subsonic, supersonic, and hypersonic.
  • By launch mode, the surface-to-surface segment is estimated to account for the largest share of the Rocket and missile market in 2023.
  • Based on launch mode, the rocket and missile market has been segmented into surface-to-surface, surface-to-air, air-to-air, air-to-surface, and subsea-to-surface.
  • The North America accounted for the largest share in rocket and missile market in 2023.

Rocket and Missile Market worth $77.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 14, 2023

Based on speed, the Rocket and missile market has been segmented into subsonic, supersonic, and hypersonic.

Key Points: 
  • Based on speed, the Rocket and missile market has been segmented into subsonic, supersonic, and hypersonic.
  • By launch mode, the surface-to-surface segment is estimated to account for the largest share of the Rocket and missile market in 2023.
  • Based on launch mode, the rocket and missile market has been segmented into surface-to-surface, surface-to-air, air-to-air, air-to-surface, and subsea-to-surface.
  • The North America accounted for the largest share in rocket and missile market in 2023.

Polyhydroxyalkanoate (PHA) Market size worth USD 232.5 Million, Globally, by 2030 at 14.3 % CAGR: Verified Market Research®

Retrieved on: 
Friday, September 8, 2023

JERSEY CITY, N.J., Sept. 8, 2023 /PRNewswire/ -- The Global Polyhydroxyalkanoate (PHA) Market is projected to grow at a CAGR of 14.3% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 78.6 Million in 2022 and is expected to reach USD 232.5 Million by the end of the forecast period.

Key Points: 
  • The report provides an in-depth analysis of the global Polyhydroxyalkanoate (PHA) Market, including its growth prospects, market trends, and market challenges.
  • Polyhydroxyalkanoate (PHA) Market is well-positioned to cater to this demand, as they offer a viable solution to replace traditional plastics.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Polyhydroxyalkanoate (PHA) Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Polyhydroxyalkanoate (PHA) Market into Type, Application Type, And Geography.

Polyhydroxyalkanoate (PHA) Market size worth USD 232.5 Million, Globally, by 2030 at 14.3 % CAGR: Verified Market Research®

Retrieved on: 
Friday, September 8, 2023

JERSEY CITY, N.J., Sept. 8, 2023 /PRNewswire/ -- The Global Polyhydroxyalkanoate (PHA) Market is projected to grow at a CAGR of 14.3% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 78.6 Million in 2022 and is expected to reach USD 232.5 Million by the end of the forecast period.

Key Points: 
  • The report provides an in-depth analysis of the global Polyhydroxyalkanoate (PHA) Market, including its growth prospects, market trends, and market challenges.
  • JERSEY CITY, N.J., Sept. 8, 2023 /PRNewswire/ -- The Global Polyhydroxyalkanoate (PHA) Market is projected to grow at a CAGR of 14.3% from 2023 to 2030, according to a new report published by Verified Market Research®.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Polyhydroxyalkanoate (PHA) Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Polyhydroxyalkanoate (PHA) Market into Type, Application Type, And Geography.

NEW LEVERAGED SINGLE-STOCK ETFS LAUNCH ON: TESLA, NVIDIA & AMD

Retrieved on: 
Tuesday, August 22, 2023

The investment program of the Fund is speculative, entails substantial risks and include asset classes and investment techniques not employed by more traditional mutual funds.

Key Points: 
  • The investment program of the Fund is speculative, entails substantial risks and include asset classes and investment techniques not employed by more traditional mutual funds.
  • Investments in the ETFs are not bank deposits and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
  • GraniteShares Leveraged Long and Inverse Daily ETFs are not suitable for all investors.
  • GraniteShares, GraniteShares ETFs, and the GraniteShares logo are registered and unregistered trademarks of GraniteShares Inc., in the United States and elsewhere.

SEAN "DIDDY" COMBS' REVOLT ANNOUNCES REVOLT WORLD, A FIRST-OF-ITS-KIND IMMERSIVE EXPERIENCE THAT EXPANDS ON ITS ANNUAL SUMMIT IN ATLANTA

Retrieved on: 
Thursday, July 27, 2023

ATLANTA, July 27, 2023 /PRNewswire/ -- Today, REVOLT, America's fastest-growing Black-owned multimedia empire, is thrilled to announce a first-of-its-kind event that reimagines the intersection of culture and creativity, REVOLT WORLD. Set to take place in Atlanta from Friday, September 22nd – Sunday, September 24th at Pangaea Studios, REVOLT WORLD presented by Walmart will include exciting performances and discussions from cultural leaders aimed to empower the Black community.

Key Points: 
  • This theme also pays homage to the global impact of Hip Hop, with a celebration of its 50th anniversary.
  • Carrying out this commitment, REVOLT WORLD will empower emerging Black leaders with access to unparalleled tools, knowledge, and life-changing opportunities.
  • As the presenting sponsor, Walmart is working alongside REVOLT to support rising Black changemakers in their journeys.
  • For more information about REVOLT WORLD and updates on the talent lineup, activations, programming, and presale tickets, please visit https://www.revolt.tv/ .

SEEDS - Access Changes Everything Unveils The Short Game - a New Twist to its Annual Allen Meisels Memorial Golf Classic

Retrieved on: 
Thursday, July 13, 2023

NEWARK, N.J., July 13, 2023 /PRNewswire/ -- SEEDS - Access Changes Everything is excited to announce its upcoming annual fundraising event, The Allen Meisels Memorial Golf Classic.

Key Points: 
  • NEWARK, N.J., July 13, 2023 /PRNewswire/ -- SEEDS - Access Changes Everything is excited to announce its upcoming annual fundraising event, The Allen Meisels Memorial Golf Classic.
  • An exciting new feature to their annual golf fundraiser is The Short Game, sponsored by 21Seeds Tequila and Allied Beverage Group.
  • John F. Castano, President + CEO of SEEDS, expressed his excitement about the addition of The Short Game, saying, "We are thrilled to add The Short Game to our Allen Meisels Golf Classic this year.
  • Registration and brunch for The Allen Meisels Golf Classic on Aug. 7 will begin at 10 a.m., with a shotgun start at 11:30 a.m.

STUDY ON PROCHONDRIX OSTEOCHONDRAL ALLOGRAFT PUBLISHED IN THE JOURNAL OF ORTHOPAEDIC SURGERY DEMONSTRATES ENCOURAGING OUTCOMES WHEN USED ON ISOLATED ARTICULAR CARTILAGE DEFECTS

Retrieved on: 
Thursday, June 29, 2023

CENTENNIAL, Colo., June 29, 2023 /PRNewswire/ -- AlloSource®, a leading innovator and manufacturer of cartilage for joint preservation, today announced the Journal of Orthopaedic Surgery published the study titled " Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee ."

Key Points: 
  • CENTENNIAL, Colo., June 29, 2023 /PRNewswire/ -- AlloSource®, a leading innovator and manufacturer of cartilage for joint preservation, today announced the Journal of Orthopaedic Surgery published the study titled " Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee ."
  • This study demonstrated encouraging patient-reported outcomes in the treatment of symptomatic articular cartilage lesions using a laser-etched osteochondral allograft, ProChondrix.
  • "ProChondrix has been a valuable addition to my cartilage restoration treatment options and my patient outcomes have been encouraging," said Dr. Mehta.
  • "The results of this study capture the potential ProChondrix has to help surgeons heal their patients needing articular cartilage repair."

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Retrieved on: 
Tuesday, June 27, 2023

“AL amyloidosis is a rare and life-threatening disease in which patients have no treatment options despite the high fatality rate.

Key Points: 
  • “AL amyloidosis is a rare and life-threatening disease in which patients have no treatment options despite the high fatality rate.
  • For two secondary endpoints, birtamimab demonstrated statistically significant improvements over placebo in a post hoc assessment of patients with Mayo Stage IV AL amyloidosis.
  • In safety evaluations, the rates of treatment emergent adverse events (TEAEs) were balanced between treatment arms among patients with Mayo Stage IV AL amyloidosis (38 TEAEs in patients treated with birtamimab compared to 39 TEAEs in patients receiving placebo).
  • Cardiac disorder was the most common class of fatal TEAEs, which is consistent with patients who have AL amyloidosis.